JP2006526639A - 生物防御のための免疫療法 - Google Patents

生物防御のための免疫療法 Download PDF

Info

Publication number
JP2006526639A
JP2006526639A JP2006514972A JP2006514972A JP2006526639A JP 2006526639 A JP2006526639 A JP 2006526639A JP 2006514972 A JP2006514972 A JP 2006514972A JP 2006514972 A JP2006514972 A JP 2006514972A JP 2006526639 A JP2006526639 A JP 2006526639A
Authority
JP
Japan
Prior art keywords
antibody
antibody fragment
group
seq
nos
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2006514972A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006526639A5 (https=
Inventor
キャサリン エス． バウディッシュ，
シャーナ フレデリクソン，
マーサ エー． ワイルド，
トシアキ マルヤマ，
メアリー ジーン ノーラン，
Original Assignee
アレクシオン ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アレクシオン ファーマシューティカルズ， インコーポレイテッド filed Critical アレクシオン ファーマシューティカルズ， インコーポレイテッド
Publication of JP2006526639A publication Critical patent/JP2006526639A/ja
Publication of JP2006526639A5 publication Critical patent/JP2006526639A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/116—Togaviridae (F); Matonaviridae (F); Flaviviridae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1278—Bacillus (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2006514972A 2003-06-02 2004-05-26 生物防御のための免疫療法 Withdrawn JP2006526639A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/452,593 US20040258699A1 (en) 2002-02-11 2003-06-02 Immunotherapeutics for biodefense
PCT/US2004/016557 WO2004110362A2 (en) 2003-06-02 2004-05-26 Immunotherapeutics for biodefense

Publications (2)

Publication Number Publication Date
JP2006526639A true JP2006526639A (ja) 2006-11-24
JP2006526639A5 JP2006526639A5 (https=) 2007-06-28

Family

ID=33551270

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006514972A Withdrawn JP2006526639A (ja) 2003-06-02 2004-05-26 生物防御のための免疫療法

Country Status (9)

Country Link
US (1) US20040258699A1 (https=)
EP (1) EP1648487A2 (https=)
JP (1) JP2006526639A (https=)
KR (1) KR20060031803A (https=)
CN (1) CN1829525A (https=)
AU (1) AU2004247034A1 (https=)
CA (1) CA2527843A1 (https=)
IL (1) IL172231A0 (https=)
WO (1) WO2004110362A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024526887A (ja) * 2021-07-22 2024-07-19 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ，アズ リプレゼンテッド バイ ザ セクレタリー オブ ザ ネイビー ベネズエラウマ脳炎ウイルスを結合し中和する単一ドメイン抗体

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1395657B1 (en) * 2000-12-05 2007-04-18 Wisconsin Alumni Research Foundation Receptor for bacillus anthracis toxin
US7658924B2 (en) * 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US7601351B1 (en) 2002-06-26 2009-10-13 Human Genome Sciences, Inc. Antibodies against protective antigen
WO2004052277A2 (en) * 2002-12-05 2004-06-24 Wisconsin Alumni Research Foundation Anthrax antitoxins
WO2005007804A2 (en) * 2003-04-10 2005-01-27 President And Fellows Of Harvard College Anthrax conjugate vaccine and antibodies
CA2560759A1 (en) * 2004-03-03 2005-12-22 Iq Corporation Human anthrax toxin neutralizing monoclonal antibodies and methods of use thereof
CA2591665C (en) * 2004-12-20 2015-05-05 Crucell Holland B.V. Binding molecules capable of neutralizing west nile virus and uses thereof
US7838252B2 (en) * 2005-02-17 2010-11-23 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating a subject having an anthrax toxin mediated condition
WO2008063147A2 (en) * 2005-03-31 2008-05-29 The General Hospital Corporation Anthrax polypeptide binding
AU2006245734C1 (en) 2005-05-12 2012-05-24 Crucell Holland B.V. Host cell specific binding molecules capable of neutralizing viruses and uses thereof
US20070202117A1 (en) * 2005-12-22 2007-08-30 Herman Groen Compositions and Methods Of Modulating the Immune Response
US7794732B2 (en) 2006-05-12 2010-09-14 Oklahoma Medical Research Foundation Anthrax compositions and methods of use and production
WO2007141274A2 (en) * 2006-06-06 2007-12-13 Crucell Holland B.V. Human binding molecules having killing activity against staphylococci and uses thereof
US8093360B2 (en) 2006-09-28 2012-01-10 Elusys Therapeutics, Inc. Antibodies that bind B. anthracis exotoxin, formulations thereof, and methods of use
EP1913955A1 (en) 2006-10-19 2008-04-23 Gerhard, Markus Novel method for treating H.pylori infections
EP2246426A4 (en) * 2008-01-29 2011-08-10 Inst Antibodies Co Ltd COMPOSITION FOR THE NEUTRALIZATION OF BOTULINUS TOXIN TYPE-A AND HUMAN ANTIBODIES AGAINST BOTULINUS TOXIN TYPE-A
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
GB0812316D0 (en) * 2008-07-07 2008-08-13 Secr Defence Antibody
US8343495B2 (en) * 2009-01-10 2013-01-01 Auburn University Equine antibodies against Bacillus anthracis for passive immunization and treatment
CN103172734A (zh) * 2013-04-07 2013-06-26 中国人民解放军南京军区军事医学研究所 人源抗炭疽毒素保护性抗原中和抗体Fab及应用
TWI606834B (zh) * 2014-10-24 2017-12-01 國立陽明大學 缺氧培養之間葉幹細胞用於修復血管內皮細胞的應用
CN104628853B (zh) * 2015-02-06 2017-10-10 中国人民解放军南京军区军事医学研究所 人源抗炭疽保护性抗原PA的抗体IgG及其应用
WO2018232144A1 (en) * 2017-06-14 2018-12-20 Monojul, Llc High-affinity anti-human folate receptor beta antibodies and methods of use
CN109134647B (zh) 2018-08-28 2020-08-04 东莞市朋志生物科技有限公司 Ns1蛋白的结合蛋白
CN109081869B (zh) 2018-08-28 2022-06-03 东莞市朋志生物科技有限公司 Ns1蛋白的结合蛋白

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2407443A1 (en) * 2000-05-04 2001-11-08 President And Fellows Of Harvard College Compounds and methods for the treatment and prevention of bacterial infection
JP2006503547A (ja) * 2002-02-11 2006-02-02 アレクシオン ファーマシューティカルズ， インコーポレイテッド 生物兵器防衛のための免疫療法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024526887A (ja) * 2021-07-22 2024-07-19 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ，アズ リプレゼンテッド バイ ザ セクレタリー オブ ザ ネイビー ベネズエラウマ脳炎ウイルスを結合し中和する単一ドメイン抗体

Also Published As

Publication number Publication date
EP1648487A2 (en) 2006-04-26
CN1829525A (zh) 2006-09-06
AU2004247034A1 (en) 2004-12-23
IL172231A0 (en) 2006-04-10
KR20060031803A (ko) 2006-04-13
US20040258699A1 (en) 2004-12-23
CA2527843A1 (en) 2004-12-23
WO2004110362A3 (en) 2005-07-28
WO2004110362A2 (en) 2004-12-23

Similar Documents

Publication Publication Date Title
JP2006526639A (ja) 生物防御のための免疫療法
JP2006503547A (ja) 生物兵器防衛のための免疫療法
CN116023478B (zh) 冠状病毒的中和抗体或其抗原结合片段
CN115710311B (zh) 冠状病毒的抗体或其抗原结合片段
RU2764740C1 (ru) Биспецифическое антитело против вируса бешенства и его применение
EP2314619A1 (en) Anti-orthopoxvirus recombinant polyclonal antibody
JP2004529647A (ja) ヒトｔｉｍｐ−１抗体
CN111606980A (zh) Sars-cov冠状病毒s2蛋白多肽及其应用
WO2022216223A1 (en) Vaccine and/or antibody for viral infection
US20240254202A1 (en) Llama-derived nanobodies binding the spike protein of novel coronavirus sars-cov-2 with neutralizing activity and application thereof
WO2019129214A1 (zh) 针对破伤风毒素的全人源单克隆中和抗体及其应用
CN117756934B (zh) 抗破伤风的纳米抗体或其抗原结合片段及其相关生物材料与应用
CN117209596B (zh) 抗非洲猪瘟病毒p72蛋白中和活性单克隆抗体2c9及其应用
CN115260306B (zh) 靶向SARS-CoV-2受体结合基序的单克隆抗体及其识别抗原表位和应用
CN117209595B (zh) 抗非洲猪瘟病毒p72蛋白中和活性单克隆抗体4f10及其应用
Kgagudi Delineating Antibody Responses Elicited by Four SARS-CoV-2 Variants against the Mu Variant
CN119039430A (zh) 靶向结核分枝杆菌MctB的保护性单克隆抗体及制备方法和应用
JP2024500313A (ja) コロナウイルス感染の検出および治療のためのポリペプチド
JP2010519916A (ja) 風疹ウイルスに特異的な抗体
Pantano Development of BSL-2 platforms for the identification of pan-neutralizing human monoclonal antibodies against Coronaviridae
CN117343170A (zh) 用于检测鼠疫耶尔森菌的抗LcrV抗体及其应用
CN117683128A (zh) 一种全人源针对鼠疫菌的保护性单克隆抗体及其应用
CN118290572A (zh) 抗狂犬病病毒全人源抗体及其组合物与应用
WO2024155381A1 (en) Antibodies for zika virus
CN120865397A (zh) 一种c型肉毒毒素受体结合域纳米抗体及其应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070514

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070514

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20070921